Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study

Qing Zhou,Mengzhao Wang,Helong Zhang,Qunying Hong,Xiaoqing Liu,Puhan Lu,Weiguo Su,Yi-Long Wu

Clinical Lung Cancer（2022）

引用 0|浏览20

暂无评分

摘要

In patients with EGFR-mutant NSCLC with brain metastasis, epitinib was well tolerable with a promising efficacy. According to the comprehensive assessment on safety and efficacy, 160 mg QD could be the recommended phase 2 dose.

查看译文

关键词

Brain metastasis,NSCLC,EGFR mutation,HMPL-813,Tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要